

ATTORNEY DOCKET NO. 14114.0342U2
SERIAL NO. 10/031,088

NOS:1-6, 9-11, 13-15, 17-45, 47, 49-64, 67-70, 73-85, 88 and conservative variations thereof and wherein the peptide has one or more glutamine residues at the carboxyl terminal end of the peptide, wherein said glutamine residue is not present in the HAV polyprotein sequence.

45. (New Claim) The peptide of claim 44, wherein the peptide comprises amino acid sequence selected from the group consisting of SEQ ID NOS:1-6, 9-11, 13-15, 17-45, 47, 49-64, 67-70, 73-85 and 88 and wherein the peptide has one or more glutamine residues at the carboxyl terminal end of the peptide, wherein said glutamine residue is not present in the HAV polyprotein sequence.

B' conclud
46. (New Claim) The peptide of claim 44, wherein the peptide consists of amino acid sequence selected from the group consisting of SEQ ID NOS:1-6, 9-11, 13-15, 17-45, 47, 49-64, 67-70, 73-85, 88 and conservative variations thereof.

47. (New Claim) The peptide of claim 46, wherein the peptide consists of amino acid sequence selected from the group consisting of SEQ ID NOS:1-6, 9-11, 13-15, 17-45, 47, 49-64, 67-70, 73-85 and 88.

REMARKS

Claims 1-43 are pending in the present application. New claims 44-47 are added herein to more clearly define the invention. Support for these new claims may be found throughout the specification and in the claims of the application as filed. Specifically, support is found in the presently pending claims and in the specification at page 8, lines 2-7 and 9-10, wherein it is recited that "[t]he synthetic peptides provided herein contain antigenic epitopes...of the major structural capsid polypeptides or non-structural peptides of HAV and further include one or more